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Abstract: Background: The COVID 19 pandemic increased publication productivity enormously
with numerous new COVID-19-related articles appearing daily, despite the fact that many health care
workers in the partially overburdened national health care systems were faced with major challenges.
Methods: In a cross-sectional, observational, retrospective study we compared and correlated 17
epidemiologic, health care system-related and health-economic factors from medical databases
and intergovernmental organisations potentially influencing the COVID-19 and non-COVID-19
publication productivity between 1 January and 30 April 2020 amongst the 30 countries most severely
affected by the pandemic. These factors were additionally correlated with the national pre-COVID-19
publication rate for the same pre-year period to identify potential changes in the general publication
behaviour. Findings: COVID-19 and non-COVID-19 publication rates correlated strongest with access
to and quality of health care (ρ = 0.80 and 0.87, p < 0.0001), COVID-19 cases per capita (ρ = 0.78 and
0.72, p < 0.0001), GDP per capita (ρ = 0.69 and 0.76, p < 0.0001), health spending per capita (ρ = 0.61
and 0.73, p < 0.0001) and the pre-COVID-19 Hirsch-Index (ρ = 0.61 and 0.62, p = 0.002 and <0.0001).
Ratios of publication rates for “Cancer”, “Diabetes” and “Stroke” in 2020 versus the pre-year period
were 0.88 ± 0.06, 1.02 ± 0.18 and 0.9 ± 0.20, resulting in a pooled ratio of 0.93 ± 0.06 for non-COVID-19
publications. Interpretation: There are marked geographic and national differences in publication
productivity during the COVID-19 pandemic. Both COVID-19- and non-COVID-19 publication
productivity correlates with epidemiologic, health care system-related and healtheconomic factors,
and pre-COVID publication expertise. Countries with a stable scientific infrastructure appear to
maintain non-COVID-19 publication productivity nearly at the pre-year level and at the same time
use their resilience to produce COVID-19 publications at high rates.
Keywords: COVID-19; Sars-CoV2, publication productivity, research activity; pandemic
1. Introduction
Despite massive measures taken worldwide, the consequences of the COVID-19 (i.e., SARS-CoV2
infection) pandemic are devastating. By the beginning of June 2020, the number of people infected
had increased to more than 6.5 million and nearly 400,000 had died from this infection [1]. Not only
clinicians focus on COVID-19 patients, but also the scientific medical community is making great efforts
to identify effective treatment options and to disseminate new knowledge as urgently as possible
for the benefit of all. This has resulted in an enormous increase in publication productivity with
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numerous new articles appearing daily in scientific journals, which is particularly surprising given
the challenges faced by many health care workers in the partially overburdened national health
care systems. We therefore sought to determine which factors could be decisive for the publication
productivity during this crisis. Thus, we compared and correlated factors (Table 1) potentially
influencing the COVID-19-related publication productivity between 1 January and 30 April 2020
amongst the 30 countries most severely affected by the pandemic. These factors were additionally
correlated with the non-COVID-19 publication rate between 1 January and 30 April 2020 and the
pre-COVID-19 publication rate for the same pre-year period to obtain information on potential changes
in the general publication behaviour.
Table 1. National factors potentially influencing COVID-19-related publication productivity.
Factors Assessed by Source of Information
Number of cases
• Absolute number
• Number/1000 inhabitants JHU [1], UN [2]
Severity of cases • Case fatality rate JHU [1]
Non-COVID-19 publication productivity
• Number of PubMed-listed
publications on “Cancer”,
“Diabetes” and “Stroke”
(sorted by countries
of affiliations)
PubMed
(www.pubmed.ncbi.nlm.nih.gov)
Pre-COVID-19 research
tradition/infrastructure
• Pre-COVID-19 H-index
• Pre-COVID-19 citable
publications by country
• Number of PubMed-listed
publications on “Cancer”,
“Diabetes” and “Stroke” in the
pre-year period
SCR [3] PubMed
National COVID-19 control measures • Stringency Index Oxford COVID-19 GovernmentResponse Tracker [4]
Research funding
• Pre-COVID-19 H-index,
citable publications SCR [3]
• Research and Development
investments % of GDP OECD [5]
• Health spending per capita OECD [5]
Number of physicians • Physicians/1000 inhabitants OECD [5]
Number of acute beds
• Acute care hospital
beds/1000 inhabitants OECD [5]
Health care quality
• Health care Access and
Quality-Index (HAQ-Index) GBDS [6]
• Global Health Security Index
(GHS-Index) NTI and JHU [7]
Health care access
• Health care Access and Quality
Index (HAQ Index) GBDS [6]
Health spending • Annual spending per capita OECD [5]
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Table 1. Cont.
Factors Assessed by Source of Information
Response to and mitigation of the spread
of an epidemic
• Rapid Response» subcategory of
Global Health Security Index
(GHS-Index)
NTI and JHU [7]
Gross domestic product (GDP)
• Gross domestic product (at
purchasing power parity) per
capita estimated for 2020 (USD)
IMF [8]
Potential future clinical trials
• Number of currently registered
COVID-19 trials
WHO COVID-19 Database
(www.clinicaltrials.gov) [9]
2. Methods
Selection of the potentially relevant factors was based both on previous non-COVID-19 articles
addressing publication productivity of nations [10,11] and on an educated guess. Only data of
highly reliable sources were retrieved to address/quantify these factors (Table 1). The sample size
of 30 countries was based on King [11], intended to result in a representative selection of countries
with high, intermediate and low (preliminary) publication output. To allow data collection despite
the dynamic evolution of the pandemic, the ranking of the countries was defined on 23 April 2020;
however, COVID-19-related numbers (except for the case fatality rates) were updated on 2 May 2020.
The number of PubMed-listed publications was determined with the search term “COVID-19 AND
country [affiliation]” and normalized by 1 million inhabitants. When using “SARS-CoV2” instead
of “COVID-19”, search hits were markedly lower and yielded various duplicates with “COVID-19”
search hits, thus we considered it an inferior search term for our analysis. Additionally, Scopus,
Web of Science and Embase were searched for “COVID-19” and categorized by the countries affiliated.
However, due to considerably lower search hits (Scopus n = 3048; Web of Science n = 998, Embase
n = 3349), these databases were not considered for our analysis. For factors impossible to quantify
precisely including “Research tradition/infrastructure”, “Research funding”, “Health care quality”
approximative surrogate markers have been used (Table 1 [2–9]). Due to the dynamic changes of the
national level of COVID-19 control measures, the stringency scores [4] were retrieved on 31 March and
30 April 2020, as we hypothesized that all of these factors could positively correlate with the number
of PubMed-listed COVID-19-related publications. In the case of publications involving authors from
institutions in different countries, each country affiliated was counted once. Due to the lack of reliable
information, the number of medical researchers, medical universities and medical research funding
per country could not be (directly) assessed.
To assess the non-COVID-19 publication rate between 1 January and 30 April 2020, we selected the
topics “Cancer”, “Diabetes” and “Stroke”, as they exhibit a high year-round publication rate worldwide.
The mean of the publications pooled from these three topics was normalized by 1 mio inhabitants
(= “non-COVID-19 publication rate 2020”) and correlated with the same 17 factors mentioned above.
Likewise, publication rates for “Cancer, “Diabetes” and “Stroke” between January 1 and 30 April 2020
were calculated (= “pre-COVID-19 publication rate”) and correlated with the factors listed in Table 1
(excluding the COVID-19-related ones). Spearman’s rank correlations were performed using SPSS 21
software (IBM Corporation: Amonk, NY, USA).
3. Results
Approximately two thirds (65.0%) of the analysed publications were affiliated with China, the USA,
Italy, the UK or France, while Australia, African and Central American countries were not represented
amongst the 30 nations with the highest COVID-19 rates. The results of the factors analysed varied
considerably between countries (Table 2); the corresponding correlation coefficients are shown in Figure 1.
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Table 2. Overview of the 30 countries most affected by COVID-19 by the end of April 2020. For each country, the COVID-19 publications and non-COVID-19
publications between January 1 and April 30 2020 are listed, including the factors analyzed.
COVID-19
Cases
Inhabitants
Per Country
COVID-19
Cases Per
Capita
COVID-19
Case Fatality
Rate
PubMed-Listed
COVID-19
Publications
PubMed-Listed
COVID-19
Publications Per
Mio Inhabitants
Non-COVID-19
Publications
Non-COVID-19
Publications
Per Mio
Inhabitants
COVID-19
Publication
Rate Per 1000
COVID-19
Cases
Pre-COVID-19
H-Index
Pre-COVID-19
Citable
Documents
Physicians
Per 1000
Inhabitants
Nurses
Per 1000
Inhabitants
Acute Care
Hospital Beds
Per 1000 Inhab
R&D
Investments
% of GDP
Health
Spending
Per Capita
(USD)
Global
Health
Security
Index
Health
Care
Access and
Quality
Score
Emergency
Preparedness
and Response
Planning Score
GDP Per
Capita
Registered
COVID-19
Studies in
WHO
Database
USA 1,104,161 331,002,651 0.00334 0.05 1084 3.27 19,239 58.12 0.85 1498 3,683,931 2.61 11.74 2.40 2.83 10,586.80 83.5 89 79.70 67,426 217
Spain 213,435 46,754,778 0.00456 0.10 167 3.57 3379 72.27 0.49 609 411,210 3.88 5.74 2.40 1.24 2341.38 65.9 92 61.90 43,007 53
Italy 207,428 60,461,826 0.00343 0.13 918 15.18 6234 103.11 3.27 752 567,666 3.99 6.71 2.60 1.39 3427.81 56.2 95 47.50 41,582 78
France 167,305 65,273,511 0.00256 0.13 339 5.19 4651 71.25 1.45 810 594,400 3.37 10.80 3.10 2.20 4964.71 68.2 92 62.90 48,640 194
Germany 164,077 83,783,942 0.00196 0.03 256 3.06 6443 76.90 1.15 844 865,665 4.25 12.93 6.00 3.13 5986.43 66.0 92 54.80 55,306 38
UK 178,685 67,886,011 0.00263 0.13 643 9.47 6684 98.46 3.49 1004 990,889 2.85 7.80 2.10 1.71 4069.57 77.9 90 91.90 48,168 35
Turkey 122,392 84,339,067 0.00145 0.02 88 1.04 1302 15.44 0.55 284 230,057 1.87 2.07 2.80 0.96 1226.59 52.4 74 49.00 29,326 13
Iran 96,448 83,992,949 0.00115 0.06 187 2.23 1866 22.22 1.55 191 121,946 NA NA NA NA NA 37.7 72 33.70 17,831 26
China 83,959 1,439,323,776 0.00006 0.06 1991 1.38 22,337 15.52 19.79 440 104,4497 2.01 2.70 NA 2.19 688.00 48.2 78 48.60 20,984 98
Russia 124,054 145,934,462 0.00085 0.01 25 0.17 633 4.34 0.28 283 114,520 4.04 8.47 NA 0.99 1513.67 44.3 75 50.10 30,819 4
Brazil 92,202 212,559,417 0.00043 0.06 119 0.56 1980 9.32 1.97 404 278,872 NA NA NA NA 1281.62 59.7 64 67.10 17,016 18
Belgium 49,517 11,589,623 0.00427 0.15 95 8.20 1533 132.27 1.34 603 175,380 3.08 10.96 5.00 2.76 4943.54 61.0 93 47.30 50,904 19
Canada 56,343 37,742,154 0.00149 0.04 298 7.90 5050 133.80 5.34 849 515,151 2.76 9.96 1.90 1.54 4974.33 75.3 94 60.70 52,144 30
Netherlands 39,989 17,134,872 0.00233 0.12 130 7.59 3392 197.96 2.31 752 355,369 NA NA 2.90 2.16 5288.44 75.6 96 79.10 60,299 14
Switzerland 29,817 8,654,622 0.00345 0.05 186 21.49 2173 251.08 4.74 669 233,184 4.30 17.23 3.60 3.37 7316.60 67.0 96 79.30 67,557 18
Portugal 25,351 10,196,709 0.00249 0.04 44 4.32 895 87.77 1.27 313 67,008 NA 6.70 3.30 1.35 2861.38 60.3 86 67.70 34,935 5
India 37,336 1,380,004,385 0.00003 0.03 297 0.22 2950 2.14 9.47 372 336,884 0.78 1.50 NA NA 208.77 46.5 41 52.40 9026 8
Peru 40,459 32,971,854 0.00123 0.03 15 0.45 105 3.18 0.62 176 9013 NA NA NA NA NA 49.2 64 51.70 15,398 0
Ireland 20,833 4,937,786 0.00422 0.05 61 12.35 765 154.93 2.68 361 59,293 3.18 12.16 2.80 1.15 4915.49 59.0 95 45.10 86,988 4
Sweden 21,520 10,099,265 0.00213 0.12 72 7.13 2313 229.03 3.44 624 22,5333 4.12 10.90 2.00 3.31 5447.11 72.1 95 62.80 55,988 7
Austria 15,558 9,006,398 0.00173 0.03 52 5.77 1246 138.35 2.08 454 120,055 5.18 6.85 5.50 3.22 5395.11 58.5 94 42.30 55,171 12
Israel 16,152 8,655,535 0.00187 0.01 83 9.59 1568 181.16 4.19 447 114,181 3.14 5.08 2.20 4.94 2779.66 47.3 85 39.90 40,336 9
Saudi
Arabia 24,097 34,813,871 0.00069 0.01 76 2.18 843 24.21 4.99 191 47,503 NA NA NA NA NA 49.3 77 32.60 5,6912 2
Japan 14,305 126,476,461 0.00011 0.02 137 1.08 6636 52.47 9.12 619 857,878 2.43 11.34 7.80 3.26 4766.07 59.8 94 53.60 46,827 4
Chile 17,008 19,116,201 0.00089 0.01 20 1.05 351 18.36 1.11 228 35,875 NA NA 2.00 0.36 2181.73 58.3 78 60.20 2715 2
South
Korea 10,780 51,269,185 0.00021 0.02 117 2.28 810 15.80 9.26 371 269,058 2.34 6.91 7.10 4.53 3191.55 70.2 90 71.50 46,451 5
Ecuador 26,336 17,643,054 0.00149 0.05 6 0.34 49 2.78 0.38 149 17,681 NA NA NA NA NA 50.1 62 39.50 11,866 0
Singapore 17,548 5,850,342 0.00300 0.00 190 32.48 894 152.81 15.09 535 269,110 NA NA NA NA NA 58.7 91 64.60 105,689 7
Poland 13,375 37,646,611 0.00036 0.04 48 1.28 1446 38.41 3.69 519 627,632 NA NA 4.80 NA 2056.36 55.4 82 47.50 35,651 9
Pakistan 18,114 220,892,340 0.00008 0.02 52 0.24 417 1.89 3.28 247 143,723 NA NA NA NA NA 35.5 38 38.70 6016 6
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The Spearman’s correlation coefficients resulting from correlations between the COVID-19,
nonCOVID-19 (i.e., publications on “Cancer”, “Diabetes” and “Stroke” published between 1 January
and 30 April 2020 and pre-COVID-19 publication rates (i.e., publications on “Cancer”, “Diabetes” and
“Stroke” published between 1 January and 30 April 2020) with the factors listed in Table 1 are shown in
Figure 1 (exact p-values in Table A1). We found weak negative correlations between the non-COVID-19
publication rate and the national Stringency Index present on 31 March and 30 April 2020 (Rho (ρ)
−0.344; p = 0.63 and ρ −0.314; p = 0.12). The COVID-19 publication rate neither correlated with these
scores present on 31 March nor on 30 April 2020 (ρ −0.27; p = 0.13 and ρ −0.18; p = 0.37).
The COVID-19 and non-COVID-19 publication rate correlated positively (ρ 0.924; p < 0.001);
the ratios of the publication rates for “Cancer”, “Diabetes” and “Stroke” 2020 vs. the pre-year period
were 0.88 ± 0.06, 1.02 ± 0.18 and 0.9 ± 0.20 (Table A2), respectively, resulting in a pooled ratio of
0.93 ± 0.06 for non-COVID-19 publications.
4. Discussion
Our results indicate that the COVID-19 publication rate of the 30 countries most affected by the
SARS-Cov2 pandemic by the end of April 2020 correlates positively with epidemiological factors
(COVID-19 cases per capita, case fatality rate), health care system-relevant (number of physicians
HAQ Index, Global Health Security Index) and economic factors (health care expenditure per capita,
gross domestic product (GDP)), and, additionally, with the publication expertise (pre-COVID-19
H-index, COVID-19 trial database). In contrast, we have not detected a significant correlation between
the COVID-19 publication productivity and the national level of stringency, number of acute care
hospital beds and research and development (R&D) investment (as percentage of GDP). The correlation
pattern we found for the COVID-19 publication rate was quite similar for the non-COVID-19-publication
and, where applicable, also for the pre-COVID-19 publication rate, suggesting that it is not COVID-19
specific (Figure 1). This even held true when the two countries with the highest absolute (China, USA)
and the highest normalized number (Singapore, Switzerland) of COVID-19 publications were excluded
from the calculation.
It appears plausible that higher numbers of COVID-19 cases per capita and higher case fatality rates
may drive publication productivity by (i) enlarging the pool of (severely ill) patients eligible for research,
(ii) potentially increasing the number of contacts between COVID-19 patients and physicians and (iii)
increasing the (social) pressure to help and thereby the motivation to publish COVID-19-related data.
On the other hand, a higher burden on the health care system is likely to reduce resources for medical
publications. The positive correlation between the number of physicians and publication productivity
supports this assumption, as countries with very high (normalized) publication rates, such as
Switzerland or Italy, have rather high numbers of physicians per 1000 inhabitants (no corresponding
information was available for Singapore, which had the highest normalized publication rate). In this
context, it would have been helpful to have information on the national proportion of (non-physician)
researchers publishing on COVID-19, who are not directly involved in patient-care. Such a “division of
labour” could explain why in some countries it was possible to “exploit” the pandemic for publications
despite the high patient-related workload. Certainly, a well-established pre-COVID research and
publication expertise may facilitate the latter. The high H-index (“pre-COVID-19 H-index”) from
previous years we found for countries such as Italy, The Netherlands or UK supports the assumption
that nations with a high COVID-19 publication rate have scientific infrastructures that enabled a high
publication productivity despite high infection and case-fatality rates. The (weaker) positive correlation
between registered COVID-19 trials and the current COVID-19 publication productivity may be rooted
in the same pre-COVID publication and research expertise.
The extent of this utility of this pre-COVID expertise during the pandemic is presumably closely
linked to health care-relevant and economic factors. The strongest correlation of the COVID-19
publication rate we found was with the HAQ-Index. This index is an approximation to assess health
care access and quality based on 32 causes from which death should not occur in the presence of
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effective care. This “amenable mortality” [6] has been repeatedly used as an indicator for the overall
performance of country’s health care system [6,12]. Except for Israel (HAQ-Index 85), all of the
ten countries with the highest normalized publication rates had a very high HAQ-Index of ≥90
(with 100 being the maximum) indicating that higher quality of health care is associated with higher
publication productivity. This obvious connection is further supported by the (weaker) correlation of
the publication rate and the Global Health Security Index.
However, it remains speculative as to how the relationship between the quality of health care and
the publication rate truly is, whether it is a coincidence or a causal association. This correlation may be
confounded by economic factors, such as health spending per capita or GDP per capita, which also
positively correlated with the publication rates. It is known from the Global Burden of Disease Study
from 2016 that the HAQ-Index and the health spending per capita strongly correlate [6]. The differences
in COVID-19 and non-COVID-19 publication rates between Italy and Spain are noticeable. Despite
similarities in demographics, COVID-19 cases per capita, case-fatality rates, HAQ-Index and many
other factors, the publication rate of Italy was more than 4 times higher for COVID-19 publications and
approximately 1.5 times higher for non-COVID-19 publications. When considering the normalized
factors, the major difference between these two countries may be the 32% higher health care spending
per capita in Italy. It is, however, conceivable that the confinements established by Spain, which at that
time were one of the strictest in the world, negatively affected scientific work and thus scientific output.
We also found a clear correlation between GDP and the publication rates for both COVID-19 and
non-COVID-19 publications, but interestingly, only weak positive correlations between R&D investment
(as percentage of GDP) and non-COVID-19 publication rate, but not with that of COVID-19 publications.
The lack of correlation with the COVID-19 publication rate may be explained by the funding of
non-medical investments irrelevant for health care-associated publications and possibly by the fact
that the R&D figures used are from 2018 and thus from the period before the pandemic. This aspect
may be of interest when analysing the publication rates in the next few years as Mendonca et al. [13]
underlined the particular importance of the percentage of GDP spent on R&D for the publication
rate by examining the impact of the financial crisis that started in 2008 on publication productivity.
They were able to show that in countries severely affected by the financial crisis, publication output
increased significantly slower in the subsequent years than in economically more stable nations.
However, the influence of GDP on the number of scientific publications has been repeatedly studied
with inconsistent results. While Cheng et al. [14] found clear correlations among publications in the
field of rheumatology, and Liang et al. [15] when analysing arthroscopy publications, other authors
were unable to demonstrate such a relationship [16,17].
Surprisingly, we found no correlation with the Rapid Response Score, a subcategory of the
GHS-Index to assess the national emergency preparedness and response planning during an endemic [7].
It contains indicators of government responses overlapping with the ones present in the Stringency
Index (e.g., structural/organizational preparedness, risk communication, travel restrictions), neither of
which correlated with the publication rates in our analysis. This may possibly indicate that while the
lockdown measures may be crucial to reduce COVID-19 transmissibility [18,19], they may not have a
major influence on publication productivity by the timepoints of our assessments.
Likewise surprising was the fact that the publication rates of the three globally common diseases
“Cancer”, “Diabetes” and “Stroke” between January 1 and April 30 2020 were unaffected for “Diabetes”,
and decreased by only 10% compared to the same period in the previous year for the two other
topics. Apparently, the level of productivity on these three non-COVID-19 topics could be nearly
maintained despite the global predominance of the topic “COVID-19” and that many journals may
have prioritized papers on COVID-19 to spread the scarce knowledge about this new virus rapidly.
This further underlines the stability of the scientific infrastructure of scientifically very productive
countries, in which, due to research units being shut down in many places, scientific work was only
possible in home offices. However, these results must be interpreted cautiously because numerous of
the non-COVID-19 publications had presumably been submitted before the pandemic. These results,
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together with our finding that most potential future studies have been registered with the WHO
database by those nations that currently have the highest publication rates, make it likely that the
majority of articles on COVID-19 will continue to originate from these countries.
Our study has some limitations: It is in the nature of exploratory studies using correlation analyses
that they are not designed to detect confounding and cannot answer the type of relationship of the
correlated factors. Thus, linear regression analyses might have produced somewhat different results.
The factors we assessed and their corresponding rho-values may help to stratify this approach.
We noticed that many of the publications included in our analysis have international affiliations.
Therefore, the focus on national publication rates we and others [10,11,14,17] have placed may be
oversimplified as the globally connected research community cannot be adequately fitted into national
terms. Furthermore, as the majority of Chinese medical publications are written in Chinese and are
not listed in Pubmed, a presumably large number of publications on COVID-19 were not considered.
Therefore, future analyses of COVID-19 publication productivity should ideally include publications in
the Chinese language to obtain a more comprehensive view on this topic. Likewise, many future trials
are not yet registered in the WHO database and it has been reported that up to 50% of registered studies
are published with a latency of several years and some even remain unpublished [20,21]. Ultimately,
our results cover just a four month period and 30 countries. In the two weeks following data analysis,
the ranking of the countries most affected had already changed and countries not assessed by us are
now amongst these top 30.
In conclusion, our analysis based on data from highly-trustful sources allowed us to rank 17 factors
potentially influencing the national publication rates on COVID-19 and non-COVID-19 publications
during the first 4 months of this pandemic. COVID-19 and non-COVID-19 publication rates correlated
strongest with the access and quality of health care, the COVID-19 cases per capita, the GDP per capita,
health spending per capita and the pre-COVID-19 H-Index. No correlations were found with the
stringency of lock-down measures, the emergency preparedness for endemics, acute care hospital
beds/1000 inhabitants, amongst others. Moreover, our results suggest that countries with a stable
scientific infrastructure may be able to maintain non-COVID-19 publication productivity nearly at the
pre-year level and at the same time use their resilience to produce COVID-19 publications at high rates.
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Appendix A
Table A1. Correlations between COVID-19-, non-COVID-19- and pre-COVID-19-publication rate and factors analysed (rho (ρ)- and p-values).
Factors
Correlation with
COVID-19
Publication Rate, rho
p-Values
Correlation with
Non-COVID-19
Publication Rate
(Cancer, Diabetes,
Stroke), rho (ρ)
p-Values
Correlation with
Pre-COVID-19
Publication Rate, rho (ρ)
p-Values
Health Care Access and Quality Index 0.80 <0.0001 0.87 <0.0001 0.86 <0.0001
COVID-19 cases per capita 0.78 <0.0001 0.72 <0.0001 NA NA
Gross domestic product per capita 0.69 <0.0001 0.76 <0.0001 0.748 <0.0001
Health spending per capita 0.61 <0.0001 0.73 <0.0001 0.72 <0.0001
Pre-COVID-19 H-index 0.61 0.002 0.62 <0.0001 0.625 <0.0001
Global Health Security Index 0.54 0.002 0.57 0.001 0.575 0.001
Physicians per 1000 inhabitants 0.47 0.045 0.63 0.004 0.582 0.009
Publication rate per 1000 COVID-19 patients 0.43 0.032 0.37 0.124 NA NA
COVID-19 WHO Database 0.39 0.042 0.29 0.082 NA NA
Case-fatality-rate 0.37 0.154 0.32 0.071 NA NA
Nurses per 1000 inhabitants 0.33 0.017 0.41 0.047 0.433 0.056
Rapid Response score 0.27 1.45 0.28 1.33 0.278 0.137
R&D investments % of GDP 0.27 0.241 0.38 0.089 0.348 0.122
Pre-COVID-19 citable documents 0.19 0.325 0.13 0.48 0.141 0.456
Acute care hospital beds per 1000 inhabitants −0.25 0.28 −0.22 0.36 −0.215 0.364
Inhabitants per country −0.63 <0.0001 −0.69 <0.001 −0.685 <0.0001
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Table A2. The absolute numbers and percentage of the 2020/2019 ratio of the COVID-19- and the non-COVID-19-publication rates for Cancer, Diabetes and Stroke
between January 1 and April 30 2020 and the pre-year period.
Cancer
1.1.–30.4.19
Cancer
1.1.–30.4.20
Cancer Percentage
2020/2019
Diabetes
1.1.–30.4.19
Diabetes
1.1.–30.4.20
Diabetes Percentage
2020/2019
Stroke
1.1.–30.4.19
Stroke
1.1.–30.4.20
Stroke Percentage
2020/2019
USA 15,839 14,354 0.91 3503 3306 0.94 1776 1579 0.89
Spain 2529 2323 0.92 726 763 1.05 308 293 0.95
Italy 5218 4528 0.87 975 1153 1.18 609 553 0.91
France 4040 3551 0.88 675 688 1.02 482 412 0.85
Germany 5139 4570 0.89 1142 1160 1.02 767 713 0.93
United
Kingdom 5023 4438 0.88 1516 1586 1.05 717 660 0.92
Turkey 1286 914 0.71 376 311 0.83 120 77 0.64
Iran 1533 1337 0.87 588 446 0.76 100 83 0.83
China 19,034 17,612 0.93 2999 3226 1.08 1483 1499 1.01
Russia 571 486 0.85 105 85 0.81 124 62 0.50
Brazil 1482 1369 0.92 443 465 1.05 183 146 0.80
Belgium 1267 1117 0.88 255 289 1.13 153 127 0.83
Canada 3686 3458 0.94 928 922 0.99 698 670 0.96
Netherlands 2698 2502 0.93 638 562 0.88 390 328 0.84
Switzerland 1603 1458 0.91 377 445 1.18 271 270 1.00
Portugal 659 618 0.94 164 194 1.18 106 83 0.78
India 2705 2008 0.74 922 778 0.84 206 164 0.80
Peru 76 59 0.78 21 34 1.62 7 12 1.71
Ireland 480 482 1.00 151 212 1.40 89 71 0.80
Sweden 1647 1459 0.89 619 590 0.95 254 264 1.04
Austria 908 888 0.98 219 224 1.02 139 134 0.96
Israel 1189 1047 0.88 364 355 0.98 164 166 1.01
Saudi
Arabia 648 564 0.87 272 242 0.89 50 37 0.74
Japan 6128 5042 0.82 1166 1044 0.90 659 550 0.83
Chile 227 218 0.96 93 102 1.10 33 31 0.94
South
Korea 702 583 0.83 141 145 1.03 102 82 0.80
Ecuador 35 27 0.77 13 12 0.92 8 10 1.25
Singapore 662 571 0.86 219 241 1.10 85 82 0.96
Poland 1276 1022 0.80 366 291 0.80 173 133 0.77
Pakistan 320 275 0.86 150 119 0.79 30 23 0.77
Mean 0.88 1.02 0.9
SD 0.06 0.18 0.20
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